RxDoctor Payments Data

Amy Goodrich

Acute Care · Baltimore, MDNPI 1649224916

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,544 of the $26,660 with a category attached, or 84.6%. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7%. Reporting peaked in 2022 at $9,625 and has fallen 71.9% since, to $2,703 in 2025. Among acute care clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,660in general payments, 2019–2025

Across 46 payments — averaging $579.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$3K
  • Sanofi$3K
  • Beigene USA, Inc.$2K
  • Epizyme, Inc.$2K
  • Eli Lilly$2K
  • plus $9K from 14 others

What the payments were for

  • Consulting fees$22,54485%
  • Speaking & faculty fees$1,7507%
  • Travel & lodging$1,2485%
  • Food & beverage$1,1174%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,660 in reported general payments places this provider in the 95th percentile of 502 acute care providers in Maryland.

See all acute care providers in Maryland

Medicare billing

Part B allowed, 2024
$25,580
Medicare patients
100
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib40$620,358
EliquisApixaban13$11,927
XareltoRivaroxaban13$6,949
ValacyclovirValacyclovir Hcl53$3,501
Gabapentin13$281
Levofloxacin13$111
Pantoprazole Sodium24$95
Ondansetron Hcl16$84
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$80
Prednisone13$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$2,445$620,35840 claims
PfizerEliquis$119$11,92713 claims
Johnson & JohnsonXarelto$243$6,94913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 502 acute care providers in Maryland.

Other acute care in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →